On April 9, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer, reported that Robert Bitterman, Chief Executive Officer and Chairman of the Board, will present at the Centri Capital Conference on Tuesday, April 14, 2026, at Nasdaq Marketsite in New York City. The presentation will also be available via a virtual webcast.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the session, Mr. Bitterman will discuss Phio’s recent clinical progress and future growth strategy, with a focus on the potential of INTASYL as a novel and differentiated approach in the field of immuno-oncology.
"We are excited to participate in the Centri Capital Conference and discuss why we believe that INTASYL PH-762 represents a paradigm shift in the treatment of cutaneous squamous cell carcinoma (cSCC)," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.
Registration Details:
Interested participants can register for the in-person or virtual event using the conference registration link provided by Centri Capital
Webcast Link: Phio Pharmaceuticals – Presentation
Event and Location: Centri Capital Conference, 151 W 43rd Street New York NY 10036
Date: Tuesday, April 14, 2026
Time: 10:30 a.m. Eastern Time
"The companies involved with the Centri Capital Conference embody the innovation and diversity shaping today’s capital markets," says Michael Aiello, CEO & Managing Partner of Centri. "We are excited to welcome them to Nasdaq for investor 1:1 meetings and meaningful exchanges with leaders from across the industry."
(Press release, Phio Pharmaceuticals, APR 9, 2026, View Source [SID1234664275])